β-catenin/CBP-IN-1

β-catenin/CBP-IN-1 is a potent and selective CBP/β-catenin antagonist, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus^[1].
In Vivo: β-catenin/CBP-IN-1 (intraperitoneal injection;1mg/kg; 42 days) has a treatment effect on liver fibrosis in hepatic fibrosis Cre/loxP/HCV-MxCreTg mouse model^[1].